Amgen Inc.

AMGNleader

Amgen is one of the world's largest biotechnology companies, pioneering the development of biologic medicines since the 1980s. Its acquisition of Horizon Therapeutics strengthened its rare disease portfolio, while MariTide, its obesity drug candidate, represents a potential blockbuster entry into the weight-loss market.

⇄ Compare

Продукты и выручка

Доля выручки продукта

Структура выручки ($33.4B)

Статические данные (загрузка финансов…)

General Medicine (Prolia, Repatha, Evenity) (35%)

Inflammation (Enbrel, Otezla) (20%)

Oncology/Hematology (25%)

Horizon Therapeutics Portfolio (20%)

Структура сегментов и ключевые клиенты

Подробности продукта

Repatha/Prolia/Xgeva30%

PCSK9 inhibitor for cholesterol and bone-targeting antibodies for osteoporosis/cancer

Enbrel20%

Anti-TNF biologic for rheumatoid arthritis and psoriasis

Tezspire/Lumakras25%

Next-gen asthma biologic and first KRAS inhibitor for lung cancer

Связи цепочки поставок

Конкуренты

AbbVie Inc.

Immunology biologics (Enbrel vs Humira)

Влияние: Long-standing rivalry

Eli Lilly and Company

Obesity and cardiometabolic drugs

Влияние: Emerging obesity competition

Pfizer Inc.

Biosimilars and inflammation

Влияние: Broad pharma competition

Макро- и рыночный контекст

제약 / 바이오Новости сектора

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Предстоящие катализаторы

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

AI-анализ

Нажмите "Получить AI-анализ" для анализа цепочки поставок Amgen Inc..

Информация о компании

Штаб-квартира

Thousand Oaks, California, USA

Основана

1980

Сотрудники

27,000+

Веб-сайт

amgen.com

Обзор сектора — 제약 / 바이오

Новости сектора